| Titolo |
Pubblicato in |
Anno |
| . BEAM vs FEAM conditioning: retrospective study in lymphoma patients undergoing autologous stem cell transplant. |
BONE MARROW TRANSPLANTATION |
2018 |
| Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi |
THE LANCET. HAEMATOLOGY |
2017 |
| Primary mediastinal large B-cell lymphoma |
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY |
2017 |
| Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial. |
BLOOD |
2017 |
| The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study. |
LEUKEMIA & LYMPHOMA |
2017 |
| Role of bone marrow biopsy in staging of patients with classical Hodgkin’s lymphoma undergoing positron emission tomography/computed tomography |
ANNALS OF HEMATOLOGY |
2017 |
| Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy. results from a monoinstitutional cohort analysis of long-term survivors |
HEMATOLOGICAL ONCOLOGY |
2017 |
| Is now the time for molecular driven therapy for diffuse large B-cell lymphoma? |
EXPERT REVIEW OF HEMATOLOGY |
2017 |
| PREDICTIVE FACTORS FOR INFECTIOUS ADVERSE EVENTS IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA TREATED WITH BENDAMUSTINE-RITUXIMAB (R)+/- R MAINTENANCE. RESULTS OF A RETROSPECTIVE ANALYSIS |
22nd Congress of the European-Hematology-AssociationHAEMATOLOGICA |
2017 |
| Repeated successful use of eltrombopag in chronic primary immune thrombocytopenia: description of an intriguing case. |
CLINICAL CASE REPORTS |
2017 |
| Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. |
HAEMATOLOGICA |
2017 |
| EFFICACY, SAFETY AND COST ANALYSIS OF SUBCUTANEOUS VS INTRAVENOUS RITUXIMAB IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH RCHOP |
HAEMATOLOGICA |
2017 |
| Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. |
THE LANCET. HAEMATOLOGY |
2017 |
| Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. |
JOURNAL OF CLINICAL ONCOLOGY |
2016 |
| CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN DIFFUSE LARGE B-CELL LYMPHOMA. A SINGLE CENTER ANALYSIS OF THE RISK FACTORS AND THE IMPACT OF CNS PROPHYLAXIS IN THE RITUXIMAB ERA |
21st Congress of the European-Hematology-AssociationHAEMATOLOGICA |
2016 |
| Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC). |
SUPPORTIVE CARE IN CANCER |
2015 |
| HIGH DOSE SEQUENTIALCHEMOTHERAPY WITH RITUXIMAB AND ASCT AS FIRST LINE THERAPY IN ADULT MCL PATIENTS: CLINICAL AND MOLECULARRESPONSE OF THE MCL0208 TRIAL, A FIL STUDY |
20th Congress of European-Hematology-AssociationHAEMATOLOGICA |
2015 |
| Autoimmune haemolytic anaemia in mantle cell lymphoma : an insidious complication associated with leukemic disease. |
HEMATOLOGICAL ONCOLOGY |
2015 |
| Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice. |
LEUKEMIA & LYMPHOMA |
2015 |
